Related Experiment Video
Updated: Aug 30, 2026
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
[Study of propoleum dosage in Peyronie's disease]
Manuel Lemourt Oliva1, Ada Rodríguez Barroso, Rafaela Bordonado Ramírez
1Servicio de Urología, Hospital Docente Quirúrgico Freyre de Andrade, La Habana, Cuba. malem@infomed.sld.cu
Objectives:
To determine the optimal dose for propoleum caps in Peyronie's disease.
Methods:
We evaluated two groups of 17 patients each, analyzing pain and plaque size on physical and ultrasound examination, before and after treatment. Group A patients received caps with 300 mg of propoleum powder daily for six months, and Group B 900 mg.
Results:
Predominant ages were between 41 and 70 years. More than half the patients in group A had pain; more than half the patients in group B did not have pain; considering both groups there were more patients without pain. Physical reduction of the plaque: Group A: 0.6 cm, Group B: 0.8 cm. Ultrasound reduction of the plaque: Group A: 1.3 cm, Group B: 0.8 cm. In the higher dose group (B) clinical and ultrasound improvement started earlier. 79.4% of the treated patients evaluated preferred improvement or slight improvement, being this result statistically significant.
Conclusions:
Pain is not always an accompanying symptom in Peyronie's disease. Both doses administered reduced the size of the plaque, but the higher one has an earlier improvement. We may consider propoleum administered in this way another treatment option for this disease, with good results and low cost.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...